

Special Issue

Novel Theranostic Agents

Message from the Guest Editor

Recent years have witnessed an expanded use of novel molecular imaging agents tied to an individually tailored treatment decision. Such a theranostic approach enables systemic or locoregional radiation of various cancer entities with α -emitting radionuclides, which are linked to the identical amino acid peptide used for PET or SPECT imaging. The unprecedented success of the theranostic concept is based on the encouraging results of recently published major trials like *NETTER-1* for imaging and therapy of neuroendocrine tumors and is further fueled by the beneficial effects of this concept for the treatment of prostate cancer. In the present Special Issue on *Novel Theranostic Agents*, original research, review articles, brief communications or comments on established theranostic agents (e.g., somatostatin receptors) as well as currently emerging compounds (e.g., C-X-C motif chemokine receptor 4) will be included. As such, this Special Issue will provide a broad overview of recent developments in the field and will concisely show how nuclear medicine can identify the *right patient at the right time for the right treatment*.

Guest Editor

Dr. Rudolf A. Werner

Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

Deadline for manuscript submissions

closed (31 December 2020)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/42581

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).